164 related articles for article (PubMed ID: 30818855)
1. Liposomal Irinotecan for Treatment of Colorectal Cancer in a Preclinical Model.
Huang JR; Lee MH; Li WS; Wu HC
Cancers (Basel); 2019 Feb; 11(3):. PubMed ID: 30818855
[TBL] [Abstract][Full Text] [Related]
2. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
[TBL] [Abstract][Full Text] [Related]
3. Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy.
Awasthi N; Schwarz MA; Zhang C; Klinz SG; Meyer-Losic F; Beaufils B; Thiagalingam A; Schwarz RE
Mol Cancer Ther; 2022 Jul; 21(7):1149-1159. PubMed ID: 35500018
[TBL] [Abstract][Full Text] [Related]
4. [Molecular mechanism of resveratrol combined with irinotecan in treatment of colorectal cancer].
Li F; Yan RY; Li KY; Wang J; Wang L; Shen H; Han CL; Liu M
Zhongguo Zhong Yao Za Zhi; 2023 Apr; 48(8):2212-2221. PubMed ID: 37282909
[TBL] [Abstract][Full Text] [Related]
5. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
Messerer CL; Ramsay EC; Waterhouse D; Ng R; Simms EM; Harasym N; Tardi P; Mayer LD; Bally MB
Clin Cancer Res; 2004 Oct; 10(19):6638-49. PubMed ID: 15475454
[TBL] [Abstract][Full Text] [Related]
6. Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme.
Yang FY; Wong TT; Teng MC; Liu RS; Lu M; Liang HF; Wei MC
J Control Release; 2012 Jun; 160(3):652-8. PubMed ID: 22405901
[TBL] [Abstract][Full Text] [Related]
7. EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo.
Fang Y; Yang W; Cheng L; Meng F; Zhang J; Zhong Z
Acta Biomater; 2017 Dec; 64():323-333. PubMed ID: 29030307
[TBL] [Abstract][Full Text] [Related]
8. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.
Kang MH; Wang J; Makena MR; Lee JS; Paz N; Hall CP; Song MM; Calderon RI; Cruz RE; Hindle A; Ko W; Fitzgerald JB; Drummond DC; Triche TJ; Reynolds CP
Clin Cancer Res; 2015 Mar; 21(5):1139-50. PubMed ID: 25733708
[TBL] [Abstract][Full Text] [Related]
9. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB
Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092
[TBL] [Abstract][Full Text] [Related]
10. Liposomal Irinotecan Achieves Significant Survival and Tumor Burden Control in a Triple Negative Breast Cancer Model of Spontaneous Metastasis.
Bernards N; Ventura M; Fricke IB; Hendriks BS; Fitzgerald J; Lee H; Zheng J
Mol Pharm; 2018 Sep; 15(9):4132-4138. PubMed ID: 30059232
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis.
Erdem ZN; Schwarz S; Drev D; Heinzle C; Reti A; Heffeter P; Hudec X; Holzmann K; Grasl-Kraupp B; Berger W; Grusch M; Marian B
Transl Oncol; 2017 Jun; 10(3):332-339. PubMed ID: 28340475
[TBL] [Abstract][Full Text] [Related]
12. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
[TBL] [Abstract][Full Text] [Related]
13. GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment.
Zou Y; Xia Y; Meng F; Zhang J; Zhong Z
Mol Pharm; 2018 Sep; 15(9):3664-3671. PubMed ID: 29570299
[TBL] [Abstract][Full Text] [Related]
14. Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study.
Aryal M; Vykhodtseva N; Zhang YZ; McDannold N
J Control Release; 2015 Apr; 204():60-9. PubMed ID: 25724272
[TBL] [Abstract][Full Text] [Related]
15. Enhanced uptake and improved anti-tumor efficacy of doxorubicin loaded fibrin gel with liposomal apatinib in colorectal cancer.
Hu Y; Wu C; Zhu C; Fu Q; Guo J; Deng L; He Y; Yang D; Cheng Y; Gao X
Int J Pharm; 2018 Dec; 552(1-2):319-327. PubMed ID: 30308269
[TBL] [Abstract][Full Text] [Related]
16. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo.
Wei Y; Gu X; Cheng L; Meng F; Storm G; Zhong Z
Acta Biomater; 2019 Jul; 92():196-204. PubMed ID: 31102765
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the therapeutic efficacy of 188Rhenium-liposomes and liposomal doxorubicin in a 4T1 murine orthotopic breast cancer model.
Liu CM; Lee WC; Yu CY; Lan KL; Chang CH; Ting G; Lee TW
Oncol Rep; 2012 Mar; 27(3):678-84. PubMed ID: 22109644
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.
Kalofonos HP; Aravantinos G; Kosmidis P; Papakostas P; Economopoulos T; Dimopoulos M; Skarlos D; Bamias A; Pectasides D; Chalkidou S; Karina M; Koutras A; Samantas E; Bacoyiannis C; Samelis GF; Basdanis G; Kalfarentzos F; Fountzilas G
Ann Oncol; 2005 Jun; 16(6):869-77. PubMed ID: 15855226
[TBL] [Abstract][Full Text] [Related]
19. cRGD-decorated biodegradable polytyrosine nanoparticles for robust encapsulation and targeted delivery of doxorubicin to colorectal cancer in vivo.
Gu X; Wei Y; Fan Q; Sun H; Cheng R; Zhong Z; Deng C
J Control Release; 2019 May; 301():110-118. PubMed ID: 30898610
[TBL] [Abstract][Full Text] [Related]
20. Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience.
Tossey JC; Reardon J; VanDeusen JB; Noonan AM; Porter K; Arango MJ
Med Oncol; 2019 Sep; 36(10):87. PubMed ID: 31494781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
